Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $11.37M rose 81.5% year over year, ahead of the +8.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 7.2% from the prior quarter. Over 3 fiscal years it compounded at -81.3% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.37M-7.2% QoQ
- Last fiscal yearDec 2025
- $311.9K-99.2% YoY
- LTMMar 2026
- $37.33M+8.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +81.5% | -100.0% | -181.5 pp |
| 1 year | -99.2% | -100.0% | -0.8 pp |
| 3-year CAGR | -81.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 311.9K USD
- Year-over-year change
- -99.2%
- 4-year CAGR
- -69.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 311.9K | -99.2% |
| FY2024 | 2024-12-31 | 37.72M | -22.9% |
| FY2023 | 2023-12-31 | 48.9M | +2.0% |
| FY2022 | 2022-12-31 | 47.93M | +36.6% |
| FY2021 | 2021-12-31 | 35.08M | — |
Selling, General & Admin vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 selling, general & admin of $37.33M is the 2nd highest of the 9 companies compared; the peer median is $22.37M.
- Its year-over-year change of +8.8% is the 2nd highest of 9, against a peer median of -9.7%.
- Over three fiscal years its annual growth of -81.3% compares with a peer median of +3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.8M | -8.8% | -5.3% | 131.2% | |
| LTM Mar 2026 | $37.33M | +8.8% | -81.3% | — | |
| LTM Mar 2026 | $30.56M | -0.6% | +16.3% | 334.5% | |
| LTM Mar 2026 | $23.53M | +30.1% | +11.7% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M | -10.5% | +40.4% | — |
CBUSCibus, Inc. | LTM Mar 2026 | $22.13M | -30.7% | +41.8% | 516.4% |
| LTM Mar 2026 | $20M | -29.6% | -4.4% | — | |
| LTM Mar 2026 | $17.18M | -7.7% | -15.7% | 6.7% | |
| LTM Mar 2026 | $15.9M | -38.9% | -12.9% | — | |
| Peer median (excluding RLMD) | $22.37M | -9.7% | +3.6% | 232.9% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 90.62M | 113.32M | 54.81M | 46.18M | 744.56K |
| Selling, General & Admin | 35.08M | 47.93M | 48.9M | 37.72M | 311.9K |
| Operating Expenses | 125.7M | 161.25M | 103.7M | 83.89M | 59.1M |
| Depreciation & Amortization | 1.26K | 2K | 103.7M | 0 | 0 |
| EBITDA | (125.75M) | (157.04M) | 4.91M | (79.98M) | (57.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (125.7M) | (161.25M) | (103.7M) | (83.89M) | (59.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (48.32K) | 4.21M | 4.91M | 3.91M | 1.72M |
| Income Before Tax | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| EPS (Diluted) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| Weighted Avg Shares | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
| Weighted Avg Shares (Diluted) | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.